Protocol Ledger

NCT05813925 · Phase III · COMPLETED

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Interventional Phase III clinical trial protocol NCT05813925 sponsored by Novo Nordisk in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-03 Enrollment: 331 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05813925
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)331 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05813925
Protocol FieldVerified Registry Value
NCT IdentifierNCT05813925
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment331 participants (ACTUAL)
Registered Start Date2023-04-03
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI